Ruxolitinib

SKU: orb1307364

Description

Ruxolitinib

Research Area

Cardiovascular Research, Cell Biology, Epigenetics & Chromatin, Signal Transduction, Stem Cell & Developmental Biology

Images & Validation

−

Key Properties

−

CAS Number	941678-49-5
MW	306.36
Purity	99.99%
Formula	C₁₇H₁₈N₆
SMILES	N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12
Target	JAK,Apoptosis,Mitophagy,Tyrosine Kinases,Autophagy
Solubility	10% DMSO+40% PEG300+5% Tween 80+45% Saline:5.7 mg/mL (18.61 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble);DMSO:242 mg/mL (789.92 mM);H2O:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

−

Target IC50	JAK2:2.8 nM (cell free)\|JAK1:3.3 nM (cell free)\|TYK2:19 nM (cell free)\|JAK3:428 nM
In Vivo	METHODS: To assay antitumor activity in vivo Ruxolitinib (3-30 mg/kg, 5% dimethyl acetamide, 0.5% methocellulose) was administered by gavage to BAL-/- mice harborin the tumor Ba/F3-JAK2V617F twice daily for three weeks. Results: Ruxolitinib significantly reduced splenomegaly and circulating levels of inflammatory cytokines and preferentially eliminated tumor cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects. METHODS: To assay antitumor activity in vivo Ruxolitinib (150 mg/kg) was orally administered to BALB/c nude mice bearin the human colorectal tumor LS411N every two days for two weeks. Results: Oral administration of Ruxolitinib significantly inhibite the growth of human colorectal tumors in vivo without causing hepatotoxicity. Read more...
In Vitro	METHODS: Ba/F3-EpoR-JAK2V617F cells were treated with Ruxolitinib (0-10 μM) for 48 h. Cell viability was measured using Cell-Titer Glo. Results: Ruxolitinib dose-dependently decreased cell viability with an IC50 of 126 nM METHODS: Hodgkin's lymphoma cells HDLM-2 were treated with Ruxolitinib (10-100 nM) for 24 h, an the expression levels of target proteins were detected by Western Blot. Results: Ruxolitinib significantly inhibite the downstream activities of p-STAT3 and p-STAT5 in a dose-dependent manner, while total STAT3 and STAT5 levels remained unchanged. Read more...
Cell Research	Cells were seeded at 2000/well of white bottom 96-well plates, treated with compounds from DMSO stocks (0.2% final DMSO concentration , and incubated for 48 hours at 37℃ith 5% CO2. Viability was measured by cellular ATP determination usin the Cell-Titer Glo luciferase reagent or viable cell counting. Values were transformed to percent Inhibition relative to Vehicle control, and IC50 curves were fitted according to nonlinear regression analysis o the data using PRISM GraphPad. Read more...
Animal Research	All o the procedures were conducted in accordance wit the US Public Health Service Policy on Humane Care and Use of Laboratory Animals. Mice were fed s andard rodent chow and provided with water ad libitum. Ba/F3-JAK2V617F cells (10^5 per mouse) were inoculated intravenously into 6- to 8-week-old f Male BAL-/- mice. Survival was monitored daily, and moribund mice were humanely killed and considered deceased at time of death. Treatment with Vehicle (5% dimethylacetamide, 0.5% methocellulose) or INCB018424 began within 24 hours of cell inoculation, twice daily by oral gavage. Hematologic parameters were measured using a Bayer Advia120 analyzed, and statistical significance was determined using Dunnett testing. Read more...

Storage & Handling

−

Storage	store at low temperature \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

Janus kinase, JAK1, JAK2, JAK, inhibit, INCB018424, INCB-018424, INCB 18424, INCB18424, INCB-18424, INCB 018424, Mitochondrial Autophagy, Mitophagy, Inhibitor, (R)-Ruxolitinib, Apoptosis, Autophagy, Ruxolitinib, Tyk2, TyrosineKinases, Tyrosine Kinases

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

25126798 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

Ruxolitinib (orb1307364)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

CAS Number:	1160597-27-2
MW:	306.37
Formula:	C₁₇H₁₈N₆

Purity:	99.86%
CAS Number:	1092939-17-7
MW:	404.36
Formula:	C₁₇H₂₁N₆O₄P

CAS Number:	3040997-52-9
MW:	507.54
Formula:	C₂₅H₂₂FN₅O₄S

Purity:	99.79%
CAS Number:	941685-37-6
MW:	306.36
Formula:	C₁₇H₁₈N₆

CAS Number:	1092939-16-6
MW:	404.45
Formula:	C₁₇H₂₀N₆O₄S

Ruxolitinib

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products

S-Ruxolitinib [orb2279205]

Ruxolitinib phosphate [orb1304597]

PPL agonist-1 [orb2814432]

Ruxolitinib (S enantiomer) [orb1301027]

Ruxolitinib sulfate [orb1688050]

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

Ruxolitinib (orb1307364)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors